SGMT — Sagimet Biosciences Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1400118 ·
Last close
$9.85
Market Cap
$702.97M
52W High
$11.45
52W Low
$4.50
ADV30
1,174,100
Next earnings
2026-11-12
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -21,567,000 -19,149,000 282,093,000 110,960,000 39,912,000
Jun 2026 0 — -15,818,000 -13,953,000 263,430,000 165,896,000 7,275,000
Mar 2026 0 — -11,713,000 -10,650,000 107,755,000 36,626,000 5,297,000
Dec 2025 0 — -10,765,000 -9,568,000 116,482,000 35,021,000 5,101,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-43,655,000
Investing CF
$-72,695,000
Financing CF
$30,700,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.28
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-390,101,000
Inventory
—
Receivables
—
ST Investments
$125,437,000
EBIT TTM
$-59,863,000
Pretax Income TTM
$-53,320,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -56,889,000 -51,038,000 116,482,000 5,101,000 111,381,000 -45,650,000
Dec 2024 0 -54,454,000 -45,567,000 160,259,000 4,454,000 155,805,000 -42,435,000
Dec 2023 2,000,000 -30,740,000 -27,876,000 96,719,000 5,654,000 91,065,000 -23,766,000
Dec 2022 0 -31,055,000 -30,499,000 33,031,000 219,981,000 -186,950,000 -24,490,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-47,079,000
OpCashFlow TTM
—
Assets (Latest)
$263,430,000
Forward EPS
$-1.35

Max Pain — expiry 2028-12-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $10.11 · call volume: 170 · put volume: 5
Expected Move to 2028-12-15: ±$9.60 (94.96%) — implied range $0.51 – $19.71 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KURA Kura Oncology, Inc. $688.17M $7.49 —
PAHC PHIBRO ANIMAL HEALTH CORP $737.01M $34.92 —
APMD Apnimed, Inc. $741.03M $17.80 —
OBX Obsidian Therapeutics, Inc. $745.61M $12.07 —
ANNX Annexon, Inc. $661.95M $3.47 —

News headlines (Yahoo Finance, 1h cache)

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-12 12:30 · Yahoo
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-29 11:00 · Yahoo
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
2026-10-23 12:55 · Yahoo
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
2026-10-23 00:10 · Yahoo
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
2026-10-22 11:00 · Yahoo
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
2026-10-15 12:35 · Yahoo
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
2026-10-09 12:18 · Yahoo
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermat
2026-10-09 11:00 · Yahoo
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
2026-10-04 01:02 · Yahoo
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
2026-10-01 20:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.